Kornimate/medical-research-clean huggingface dataset:
role of intralipid in management of organophosphorus poisoning

Conditions: Organophosphorus Poisoning

Summary: aim of the study: to assess the role of intralipid emulsion in the acute man-agement of organophosphorus toxicity and its benefits in de-creasing mortality rates among victims.

organophosphates (ops) are cholinesterase inhibitors that are widely used as pesticides and organophosphate (op) poisoning is an important public health concern in egypt especially in the rural farming population. organophosphate toxicity lead to a characteristic toxidrome that includes muscarinic, nicotinic and central nervous system signs and symptoms and, without proper and early antidotal treatment, death. a new antidote is the need of the hour. lipid emulsion being inexpensive, easily available and effective in management of other lipid soluble toxins may be a novel option. the exact mechanisms by which ile exert their beneficial effects are not fully understood, and several have suggested synergistic effects of several mechanisms. the mechanisms of action can be divided into intravascular, membrane, and intracellular effects. the original theory explaining the mechanism of lipid rescue was that of "lipid sink", suggesting sequestration of lipophilic compounds to an expanded intravascular lipid phase, extracting the offending agent from the target tissue, and reversing the toxicity. other hypotheses relate to the mechanism by which iles facilitate cardiac rescue from drug poisoning. these include: 1. increasing myocardial energy substrate delivery and a direct cardiotonic effect of ile on the poisoned heart. 2. an effect of ile on calcium ion channels through high levels of long-chain fatty acids, leading to increased cardiomyocyte calcium and positive inotropic effect.

Eligibility criteria:
inclusion criteria: * age group of 18-60 years who are exposed to organophosphorus compounds. * clinical manifestations of organophosphorus toxidromes (hyper-salivation, lacrimation, sweating, urinary incontinence, di-arrhea, vomiting and abdominal pain). exclusion criteria: 1. patient or relative in charge refusal. 2. chronic renal or liver disease manifested by history, clinical and investigatory diagnosis. 3. previous history of acute or chronic pancreatitis 4. combined poisoning with non op compounds 5. asymptomatic patients. 6. contraindications to intralipid emulsion as: * disturbances of normal fat metabolism such as patho-logic hyperlipemia manifested by history, clinical and investigatory diagnosis. * lipoid nephrosis manifested by history, clinical and investigatory diagnosis.

Keywords: intralipid, organophosphorus poisoning
strontium compared with radiation therapy in treating patients with hormone-refractory prostate cancer with painful bone metastases

Conditions: Metastatic Cancer; Prostate Cancer

Summary: rationale: radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. this may be an effective treatment for prostate cancer. purpose: randomized phase iii trial to compare the effectiveness of strontium or radiation therapy in treating patients with prostate cancer that is refractory to hormone therapy who have painful bone metastases.

objectives: i. compare, in a randomized phase iii setting, the subjective response rate, time to progression, and survival of patients with hormone-refractory prostate cancer with painful osseous metastases treated with either strontium-89 or palliative local radiotherapy. ii. compare the quality of life achieved on these two regimens. iii. determine the toxicity and morbidity of treatment on these two regimens. iv. compare the cost effectiveness of these two regimens. outline: randomized study. arm i: radioisotope therapy. strontium-89 chloride, strontium-89. arm ii: radiotherapy. involved-field irradiation (equipment unspecified). projected accrual: 200 patients will be entered over 2 years.

Eligibility criteria:
disease characteristics: histologically or cytologically proven carcinoma of the prostate that has relapsed subsequent to chemical or surgical castration and/or antiandrogen therapy painful, unirradiated osseous metastasis required documentation by bone scan and x-ray required number and extent of metastases determined according to soloway and fitting grades 1-3 prior hormonal therapy must have lasted at least 3 months and must be continued until completion of this study no imminent paraplegia related to metastases no uncorrectable urinary incontinence patient characteristics: age: any age performance status: who 0-2 hematopoietic: wbc greater than 3,500 platelets greater than 150,000 hepatic: not specified renal: creatinine no greater than 2.2 mg/dl (200 micromoles/liter) other: no calcium supplementation no second malignancy except basal cell skin cancer prior concurrent therapy: biologic therapy: not specified chemotherapy: no restriction endocrine therapy: prior and concurrent hormonal therapy required radiotherapy: no prior strontium-89 no prior hemibody or total-body irradiation prior local-field irradiation for bone metastases allowed provided new site of painful metastases exists surgery: surgical castration allowed

Keywords: recurrent prostate cancer bone metastases
effectiveness of computer-based cognitive training in age-related cognitive decline

Conditions: Age-related Cognitive Decline

Summary: background: ageing is frequently accompanied by physiological changes that might result in a deterioration in physical and cognitive abilities, which frequently leads to institutionalization or the loss of autonomy. mild cognitive impairment (mci) is an intermediate state between normal cognitive aging and early dementia, the optimal period to intervene with preventive strategies and early treatments. thus, the current study intends to investigate the effects of aerobic and computer-based cognitive training on age-related cognitive decline. methods: this is a single-blinded, randomized controlled trial. elderly patients with mild cognitive impairment (n = 60) will be randomized to 2 arms and treated for 12 weeks: arm 1 (aerobic exercise and computerized cognitive training) and arm 2 (placebo; will not receive any intervention). outcome measure used were montreal cognitive assessment (moca) test, barthel index (bi) and short form survey-12 (sf-12). statistical analysis: to compare the baseline characteristics and outcome variables between the two groups, independent t-tests was employed. a two-way repeated measures anova was utilized to determine the interaction effect of time (baseline, post-treatment, and follow-up) and group (intervention vs. control) on the outcome measures.


Eligibility criteria:
inclusion criteria: * who fulfilled mci criteria \[10\]: (1) subjective cognitive concerns; (2) objective cognitive impairment in memory, executive function, attention, and/or language; (3) preserved activities of daily living; and (4) absence of dementia * literate * had adequate visual, auditory, and fine motor skills. exclusion criteria: * major depression (scored \> 9 in the geriatric depression scale, gds-15) \[11\] * schizophrenia * substance abuse * parkinsonism * conditions affecting gait (eg, severe osteoarthritis, previous stroke), * participated in any cognitive training program during last 6 months \> 2 h/week * acsm contraindications to exercise or other factors that make exercise impossible or unsafe * cognitive enhancers, or anticholinergics

Keywords: cognition computer based cognitive training aerobic training exercises
anecortave acetate in patients with open-angle glaucoma

Conditions: Open-angle Glaucoma

Summary: the purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of anecortave acetate depot for treatment of elevated intraocular pressure (iop) in patients with open-angle glaucoma.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older with open-angle glaucoma. * other protocol-defined inclusion criteria may apply. exclusion criteria: * patients with open-angle glaucoma with a pseudoexfoliation or pigment dispersion component. * other protocol-defined exclusion criteria may apply.

Keywords: open-angle glaucoma
workplace tobacco cessation and oral cancer screening study

Conditions: Tobacco Cessation; Oral Cancer

Summary: tata memorial hospital has initiated workplace tobacco cessation and oral cancer screening programme in chemical industry at khed, ratnagiri. appropriate interventions for tobacco cessation will be carried at monthly intervals for twelve months duration. the tobacco cessation rates based on history will be validated with the urinary cotinine levels.

the prevalence of tobacco use in india among men has been reported to be high in most parts (generally exceeding 50%). it's use is more common in rural areas as compared to urban areas. oral cancer, the main cause of which is tobacco, is common in men in developing countries and the most common cancer among men in india. the five year survival rate for oral and pharyngeal cancers even in premier institute like the tata memorial hospital ranges from a poor 8% (hypo pharynx) to 43% (lower lip). evidence has shown that cessation is the only intervention with the potential to reduce tobacco related mortality in the short- term and medium- term. an emphasis on prevention of tobacco consumption will, in the short run, only have a limited positive effect on tobacco related morbidity and mortality, as prevention strategies do not affect existing consumers. workplace tobacco cessation activities in india are still in rudimentary stage. in the proposed study of one year duration, professional help in the form focus group discussion, one to one counseling and pharmacotherapy will be provided to the employees by a team of doctors and counsellors from tata memorial hospital. self reporting of tobacco history will be validated with biochemical test. this will add objectivity to the programme, so that, if successful, it can be replicated as a model to promote tobacco control activities at other workplaces. naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers will be done by doctors from the tata memorial hospital. the employees with lesions may be referred for further management, if required. nursing staff and doctors attached to the industry and from the local referral hospital will be invited to participate as trainees during the active intervention sessions. the long term objective of this initiative is to establish a model workplace tobacco cessation and oral cancer screening programme. it will contribute to the human resource and infrastructure development for tobacco cessation services at the industrial unit and at the local referral hospital. proposed tobacco cessation services in the chemical industry would be of great help for boosting anti - tobacco activities not only in the particular factory unit but also in the nearby industrial and residential zone.

Eligibility criteria:
inclusion criteria: * all 104 employees working in the chemical industrial unit at khed, ratnagiri, are eligible to participate. exclusion criteria: * there are no exclusion criteria.

Keywords: tobacco cessation behavioral therapy pharmacotherapy workplace oral cancer screening tobacco quit rates
differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced mri

Conditions: Bone Cancer; Chondrosarcoma; Ewing's Sarcoma; Osteosarcoma; Rhabdomyosarcoma; Bone Necrosis; Bone Sarcoma; Osteomyelitis

Summary: this pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (mri). imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

background; in this study, t1, t2, and t2\* represent parameters of magnetic resonance imaging (mri). the t1 relaxation time, also known as the spin-lattice relaxation time, is a measure of how quickly the net magnetization vector (nmv) recovers to its ground state in the direction of b0. t1 is assessed immediately post-contrast. a t1-weighted image (t1wi ) is one of the basic pulse sequences in mri and demonstrates differences in the t1 relaxation times of tissues. a t1wi relies upon the longitudinal relaxation of a tissue's net magnetization vector (nmv). t2 is a time constant for the decay of transverse magnetization arising from natural interactions at the atomic or molecular levels, and be considered the "natural" or "true" t2 of the tissue. however, in any nuclear magnetic resonance (nmr) experiment, transverse magnetization decays much faster than would be predicted by natural atomic and molecular mechanisms. accordingly, t2 \* is the time constant for the decay of transverse magnetization as observed in a tissue during a mri scan, and be considered the"effective t2" (represented as t2\*). t2\* is always ≤ t2. in this study, t2 \* is assessed after 24 hours. outline: patients receive ferumoxytol intravenously (iv) and then undergo ferumoxytol-enhanced mri up to 1 hour after infusion and up to 24 hours post-infusion. primary objectives: * establish magnetic resonance (mr) imaging characteristics of bone sarcomas and osteomyelitis based on their ferumoxytol-enhancement on relatively early post-contrast t1-weighted images. * establish mr imaging characteristics of bone sarcomas and osteomyelitis based on their ferumoxytol-enhancement on delayed postcontrast t2-weighted images. * establish t2-weighted mr imaging characteristics of iron-labeled mesenchymal stem cell (msc) in osteonecrotic bone over time, before and after surgical core decompression and bone marrow implantation. * adding a second branch for patients who can not receive ferumoxytol but still getting the mri exam. these patients will server as controls.

Eligibility criteria:
inclusion criteria * age 10 to 21 years * suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis * informed consent with assent as appropriate. exclusion criteria * contraindication to mri * presence of metal implants * need for sedation or anesthesia * claustrophobia * hemosiderosis or hemochromatosis * history of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study * females who are pregnancy or nursing
sensitivity/specificity study of non-invasive imaging for melanoma diagnosis

Conditions: Melanoma

Summary: the purpose of this study is to show how well a new device, confocal microscope, works to detect malignant melanoma, a type of skin cancer.


Eligibility criteria:
inclusion criteria: * age 12 or older * patient who has already been selected by their dermatologist for biopsy of a suspicious pigmented lesion and who consents to participate in the study * signed informed consent exclusion criteria: * age \< 12 years
anesthesia for obese patients: desflurane versus xenon

Conditions: Obesity

Summary: obesity is increasing in france, resulting in an increased demand for bariatric surgery. however obesity also alters physiopathological pathways and the pharmacokinetics of anesthestic agents. the investigators objective is to compare, among morbidly obese patients, the immediate and intermediary emergence kinetics after balanced anesthesia using remifentanil associated either with desflurane (reference arm) or with xenon (experimental arm).


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i to iii * requires bariatric surgery * body mass index (bmi) \>= 35 kg/m2 * patient speaks and writes french * patient has signed consent form * patient enrolled in a social security program exclusion criteria: * patient refuses to sign consent * asa iv or more * patient is pregnant or breastfeeding * history of hyperthermy (or suspicion, or family history thereof) * history of liver disease, icterus, unexplained fever, or eosinophilia after administration of a halogen anesthesia * patient has symptomatic gastro-oesophagean reflux * patient has hypersensitivity to one or more of the following substances: propofol, remifentanil, celocurine, cisatracurium, rocuronium, desflurane, xenon, paracetamol, ketoprofen, nefopam, tramadol * patient has obstructive respiratory failure (chronic obstruction pneumopathy, asthma) or has heart disease with severly altered cardiac function * patient has high intracranial pressure * patient requires high concentrations of oxygen (fio2\>40%) * patient has a neuro-sensorial deficient which prevents reading, writing, or response to simple oral commands (severe deafness, language impairment...)in the absence of a prothesis * patient has a psychiatric pathology, or chronically consumes alcohol or other mind-altering substance * patient has had general anesthesia in the last 15 days * patient under guardianship * impossible to correctly communicate information to the patient * absence of efficient contraception for women of childbearing age * participation in another study within the last 3 months

Keywords: bariatric surgery anesthesia
complete versus partial preservation of denonvilliers' fascia on urogenital function in locally advanced rectal cancer

Conditions: Rectal Cancer; Advanced Cancer

Summary: total mesorectal resection (tme) is the standard surgical method for locally advanced rectal cancer, which significantly reduces the local recurrence rate. however, the incidence of urogenital dysfunction is higher. studies found that denonvilliers' fascia contains autonomic nerves that may regulate urogenital function, while traditional tme surgery resects part of it. recent studies found that complete preservation of denonvilliers' fascia could improve urogenital in selected patients with rectal cancer. locally advanced patient (t3-4 and/or n+, m0) accounts for a high proportion of mid-low rectal cancer. however, whether these patients can benefit from it has not fully been demonstrated. this project conducts a multi-center randomized controlled study to evaluate the effects of complete preservation and partial preservation of denonvilliers' fascia on postoperative urogenital function of locally advanced non-anterior mid-low rectal cancer.


Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of rectal adenocarcinoma; 2. preoperative staging ct3-4 and or n+，m0 rectal cancer (ajcc- 7th); 3. non-anterior wall, mid-low rectal cancer from 0 to 12 cm from the anal verge measured by rigid proctoscope; 4. r0 surgical results is expected by transabdominal or transanal tme/tsme; 5. 18 \< age (years) \< 71, informed consent; 6. normal erection function (iief-5\>21), ejaculation function grading as i level, fsfi \> 26, normal urinary function (bladder residual urine\<100ml); 7. preoperative asa grade i \~ iii, no serious systemic disease; exclusion criteria: 1. preoperatively confirmed peritoneum or distant metastasis; 2. intraoperative confirmed invasion of surrounding tissues or organs, cannot be r0 resected; 3. with other malignant diseases; 4. with acute ileus, perforation or hemorrhage,need emergency surgery; 5. critical organs dysfunction, unable to tolerate laparoscopic surgery; 6. with severe mental illness, cannot be evaluated;

Keywords: urogenital function denonvilliers' fascia
is-002 phase 2 prostate cancer study

Conditions: Prostate Cancer

Summary: phase 2 randomized controlled multi-center study of is-002, in conjunction with near-infrared (nir) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostatectomy (rarp) with (extended) pelvic lymph node dissection ((e)plnd) using the da vinci® x/xi surgical system with firefly® fluorescence imaging.


Eligibility criteria:
inclusion criteria 1. subjects aged 18 to 75. 2. subject has a confirmed adenocarcinoma of the prostate as defined by (histo-) pathology. 3. subject has capra ≥6; or ≥t3 disease on imaging (trus and/or mri); or a gleason sum score ≥8; or regional lymphadenopathy suspicious for nodal metastases on imaging. 4. subject is scheduled to undergo robotic-assisted radical prostatectomy (rarp) with (extended) pelvic lymph node dissection ((e)plnd) using a da vinci® x/xi surgical system equipped with firefly® fluorescence imaging. 5. subject is willing and able to provide written informed consent. 6. subject can comply with the study procedures and study visits and understands an informed consent document. exclusion criteria 1. subject has known bone metastasis. 2. subject has known active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. 3. subject has a known history of acute or chronic liver or kidney disease. • renal function at screening: i. creatinine clearance: \<50 ml/min as determined using the cockcroft-gault formula ii. albumin: \<lln • hepatic function at screening: i. ast and/or alt: \>2.5x uln ii. total bilirubin (serum): \>1.5x uln 4. subject has received neo-adjuvant therapy, radiation therapy, focal ablation therapy, hormonal therapy, or androgen deprivation therapy within the last 4 months. 5. subject is currently receiving an investigational therapeutic agent; or has participated in a study of an investigational therapeutic agent within the past 6 months prior to the day of is-002 infusion; or is involved in a significant risk investigational device study within the past 6 months prior to the day of is-002 infusion. 6. subject has any other condition or personal circumstance that, in the judgment of the site investigator, might interfere with the collection of complete quality data or represents an unacceptable safety profile.
analysis and evaluation of smoking treatment with cytisine

Conditions: Moderate or Severe Tobacco Use Disorder

Summary: the lack of clinical studies on the use of cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

the study is observational, retrospective and monocentric, and aims to evaluate patients who performed an initial pneumological examination at the anti-smoking center of the national institute regina elena tumors due to smoking cessation in the reference period. to such patients, affected of moderate or severe tobacco use disorder, drug therapy was prescribed with cytisine 1.5 mg, with the aim of evaluating treatment adherence, efficacy and tolerability of cytisine as monotherapy in the treatment of moderate or moderate tobacco use disorder serious. responding patients will be taken into consideration for the study consecutively to the criteria established and pertaining to the anti-smoking center of the national cancer institute regina elena in the period between 02/01/2023 and 11/30/2023 on first and subsequent visits controls.

Eligibility criteria:
inclusion criteria: * patients aged \> 18 years; * patients suffering from moderate or severe tobacco use disorder; * prescription of pharmacological therapy with cytisine; * patients returned to the 1st check-up on schedule; exclusion criteria: * patients with contraindications to taking cytisine and partial receptor agonists nicotinic cholinergics; * patients undergoing pharmacological or physical treatment for neoplastic pathology; * pregnant or breastfeeding women; * patients for whom specific information for objective assessments is not available;
study to examine the effect of hki-272 on rhythms of the heart (cardiac repolarization)

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether hki-272 affects the rhythms of the heart (cardiac repolarization).


Eligibility criteria:
inclusion criteria: * men or women of nonchildbearing potential, * 18-50 years old. * healthy as determined by the investigator, including physical examination, laboratory test results, and medical history.

Keywords: thorough qtc study